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Summary
Epilepsy is a common chronic disorder of the brain and can be seen at all ages with a higher prevalence in developing countries. Adjunctive 
therapy with antiepileptic drugs (AEDs) is the gold standard in treatment of epilepsy. Lacosamide (LCM) is a novel AED which is approved for 
adjunctive therapy for the treatment of partial-onset seizures. Recently 3 Phase II/III placebo controlled clinical trials with similar designs were 
conducted to investigate the efficacy and safety of lacosamide (LCM) administered as adjunctive therapy with other AEDs. Data collected 
from those studies were pooled, re-analyzed and presented in this review article. Results revealed that LCM is well tolerated and effective in 
seizure reduction as adjunctive therapy in patients with uncontrolled partial-onset seizures.
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Özet
Epilepsi sık görülen, kronik, serebral bir hastalıktır ve daha çok gelişmekte olan ülkelerde, her yaştaki bireyde karşımıza çıkabilir. Günümüzde 
antiepileptik ilaçlar (AEİ) ile adjunktif tedavi epilepsi tedavisinde standart olarak uygulanmaktadır. Lakosamit (LCM) parsiyel başlangıçlı nö-
betlerin adjunktif tedavisinde kullanımı için onay almış bir AEİ’tır. Yakın zamanda LCM’in etkililiğini ve güvenliliğini araştırmak amacıyla, diğer 
AEİ’lar ile beraber adjunktif tedavi olarak LCM’in uygulandığı, benzer tasarımlı, plasebo-kontrollü faz II/III klinik çalışmalar gerçekleştirilmiştir. 
Bu çalışmalardan elde edilen veriler ile bir veri havuzu oluşturulmuş ve üç çalışmadan toplanan bu veriler yeniden analiz edilmiş ve bu derle-
mede sunulmaktadır. Sonuçlar LCM’in iyi tolere edildiğini ayrıca kontrolsüz parsiyel başlangıçlı nöbetleri olan hastalarda nöbetlerin görülme 
sıklığını azalttığını ortaya koymuştur.
Anahtar sözcükler: Antiepileptik ilaçlar; epilepsili yetişkinler; lakosamit.
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Introduction
Epilepsy is a chronic disorder of the brain and can be seen 
at all ages. It is anticipated that approximately 50 million 
people around the world suffer from epilepsy and most of 
the epileptic population (nearly 80%) is found in the devel-
oping countries. People with epilepsy and their families can 
suffer from discrimination and have difficulties especially in 
their workplaces.[1] 
In developed countries, annual incidence of epilepsy is re-
ported as 24-53 cases per 100,000 person-years. Age ad-
justed incidence of all unprovoked seizures are expected to 
be at 61 per 100,000.[2] Age adjusted prevalence of epilepsy 
varies and it is reported between 4 to 8 per 1,000 popula-
tion in most studies.[3] The average incidence of epilepsy in 
United States of America is estimated as 48 out of 100,000 
people corresponding to 150,000 people per year. Consid-
ering the lifetime prevalence, 16.5 per 1,000 people report-
ed that they had experienced epilepsy in their life.[4]
Epidemiologic research shows that epilepsy prevalence is 
higher in developing countries such as 18.5 per a popula-
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tion of 1,000.[5] Various epidemiologic reports are available 
from diverse regions of Turkey mentioning similar active 
prevalence rates of 5 to 8.5.[6,7]
Adjunctive therapy with antiepileptic drugs (AEDs) is the 
gold standard in treatment of epilepsy in patients with re-
fractory epilepsy.[8] Lacosamide (LCM) is a novel AED which 
is approved for adjunctive therapy for the treatment of par-
tial-onset seizures with or without secondary generaliza-
tion in patients with epilepsy aged 16 years or older.[9]
Pharmacology
Mechanism of action
Lacosamide selectively enhances the slow inactivation state 
of voltage-gated sodium channels (VGSCs) and increase the 
proportion of channels entering the slow inactivation state. 
Although, it does not appear to delay their recovery from 
slow inactivation, it has a unique effect of reducing the 
long-term availability of VGSCs, thus stabilising the neuro-
nal membrane, guarding against hyperexcitability and re-
petitive neuronal firing.[10,11,12]
Pharmacokinetics of lacosamide
Lacosamide is rapidly and completely absorbed (~100% 
bioavailability). Tmax (time to maximum plasma concentra-
tion) is achieved within 0.5–4 hours following oral adminis-
tration. The extent and rate of lacosamide absorption is not 
affected by food. Less than 15% of circulating lacosamide 
is bound to plasma proteins. The volume of distribution 
of lacosamide is approximately 0.6 L/kg. The elimination 
half-life of the unchanged drug is approximately 13 hours. 
Following twice-daily dosing, steady state plasma concen-
trations are achieved after a 3-day period. The pharmaco-
kinetics is dose-proportional and constant over time, with 
low intra- and inter-subject variability. 
Pharmaceutical forms
LCM is approved and available in Turkey with 50, 100, 150 
mg strengths as oral tablets. LCM’s 10 mg/ mL IV infusion 
form is also approved in Turkey. IV form of LCM provides 
an alternative solution for physicians and patients when 
oral administration is temporarily not feasible since IV for-
mulation is proven to be bioequivalent to the oral tablet 
form.
Drug–drug interactions
Preclinical in vitro studies indicate that the activity of CY-
P1A2, 2B6, and 2C9 are not induced, and CYP1A1, 1A2, 2A6, 
2B6, 2C8, 2C9, 2D6 and 2E1 are not inhibited by lacosamide.
[9] Lacosamide does not inhibit or induce CYP2C19 or CY-
P3A4 in vivo and does not induce or inhibit hepatic micro-
somal enzymes.[9]
Interaction with AEDs
In drug–drug interaction studies, lacosamide did not sta-
tistically affect the plasma concentrations of valproic acid 
(VPA), and lacosamide plasma concentrations were not af-
fected by VPA. Available data indicate that the overall sys-
temic exposure of lacosamide may be decreased by 25% 
during concomitant treatment with carbamazepine (CBZ), 
phenytoin (PHT) and phenobarbital (PB).[9] A pooled analysis 
of AED plasma concentrations in subjects with partial-onset 
seizures showed that that steady-state plasma concentra-
tions of levetiracetam (LEV), CBZ, lamotrigine (LTG), topira-
mate (TPM), oxcarbazepine (OXC), PHT, valproate (VPA), PB, 
gabapentin (GBP), clonazepam (CLZ), and zonisamide (ZNS) 
were affected by concomitant intake of lacosamide at any 
dose.[13,14]
Interaction with other medicinal products
In a drug–drug interaction study, there was no interaction 
between lacosamide and the oral contraceptives, ethinyl-
estradiol and levonorgestrel.[9] Furthermore, progesterone 
concentrations were not affected.[9]
Other drug–drug interaction studies have shown that lacos-
amide had no effect on the pharmacokinetics of digoxin, 
and that there was no clinically relevant interaction be-
tween lacosamide and metformin or omeprazole.[9]
Efficacy and safety
Efficacy with concomitant AEDs
Lacosamide appears to be mechanistically distinct from 
other AEDs, including traditional sodium channel blocking 
AEDs such as OXC, LTG, CBZ and PHT. The precise mecha-
nism by which lacosamide exerts its anti-epileptic effects in 
humans remains to be fully elucidated. 
In pooled clinical trials lacosamide showed additional effi-
cacy regardless of the specific concomitant AEDs adminis-
tered. Most patients in this pooled, secondary analysis had 
been treated with multiple lifetime AEDs, had a long history 
of epilepsy, and were utilizing ≥2 concomitant AEDs prior to 
baseline. Number of subjects on monotherapy was too low 
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to allow a meaningful comparison of individual combina-
tions. This analysis suggests that LCM can offer additional 
efficacy, regardless of existing concomitant AED use.[15]
Side effects
Serious adverse events were not seen in clinical trials for 
epilepsy after 6 years of testing. Non-serious adverse events 
are seen mainly during titration. Side effects include ataxia, 
dizziness, nystagmus and nausea. These side effects are all 
dose related. There were not idiosynchratic side effects so 
far.
Formulations, dosage schedule-ease of use
PB, VPA, PHT/fosphenytoin, LEV and LCM have IV formu-
lations. So far no other new AEDs have IV formulations or 
are planning to have them. LEV and LTG are available in 
extended release oral preparations in USA. Since oral tab-
let and the IV forms are bioequivalent, the ability to switch 
between each other without changing the dose, provides 
convenience to the physicians and the patients.
Phase II/III clınıcal trıals
To further evaluate the role of specific AED combinations in 
clinical outcome, data obtained from 3 clinical trials were 
combined and analyzed. Post hoc exploratory analyses 
were performed on the lacosamide pooled Phase II/III trial 
data (SP667, SP754, SP755) which include only patients who 
were taking at least 1 traditional sodium channel blocking 
AED (oxcarbazepine, carbamazepine, lamotrigine or phe-
nytoin ) as part of their concomitant treatment regimen.
Patient eligibility
Patients with uncontrolled partial-onset seizures with or 
without secondary generalization for ≥2 years despite prior 
therapy with ≥2 AEDs, with or without additional vagus 
nerve stimulation (VNS), aged between 16-70 years, with 
an average of at least 4 partial-onset seizures per 28 days; 
seizure-free period ≤21 days in the 8 weeks prior to baseline 
and during the 8-week baseline phase, being treated with 
1-3 concomitant AEDs (1-2 in SP667) were included in these 
studies.
Study designs
The primary evaluation of lacosamide for adjunctive 
therapy in adults with partial-onset seizures is based on 3 
similarly designed phase II/III pivotal clinical trials: Study 1 
(Phase II, n=418, conducted in the US and Europe), Study 2 
(Phase III, n=485, conducted in Europe and Australia), and 
Study 3 (Phase III, n=405, conducted in the US). The 3 trials 
were similar in design; all were multi-central, randomized, 
double-blind, placebo-controlled trials to assess the effica-
cy and safety of LCM as adjunctive therapy in adult subjects 
with partial-onset seizures.[16,17,18,19]
All 3 trials were powered to be adequate and well-controlled 
studies to evaluate the efficacy and safety of the oral formu-
lations of lacosamide 200, 400, or 600 mg/day vs. placebo in 
patients with refractory partial-onset seizures taking 1 to 3 
AEDs, with or without VNS.
Each of these trials used a fixed-dose, forced-titration de-
sign and included a Baseline Phase of 8 weeks to evaluate 
the baseline seizure frequency. Other phases of these open 
label studies included a Titration Phase (4- or 6-weeks), a 
Maintenance Phase (12-week), and a Taper or Transition 
Phase (2- to 3-weeks).[16,17,18,19]
After randomization, the patients began double-blind 
treatment as follows: a 4- (Study 2) or 6-weeks (Studies 1 
and 3) forced titration up to the respective randomized 
dose of LCM (200, 400, or 600 mg/day) or placebo (a 1-step, 
back-titration of LCM 100 mg/day or placebo was allowed 
in the case of intolerable adverse events at the end of the 
Titration Phase); a 12-weeks Maintenance Phase on the 
achieved randomized (or back-titrated) dose; and either a 
2-weeks Transition Phase or a 2- (Study 2) or 3-weeks (Stud-
ies 1 and 3) Taper Phase. The 2-weeks Transition Phase that 
brought patients to a dose of LCM 200mg/day was required 
for patients who completed the Maintenance Phase and 
who chose to enroll in an open-label extension trial of LCM. 
The 2-to 3-weeks Taper Phase (during which dosing was re-
duced by weekly increments of 200 mg/day) was required 
for patients who chose not to enroll in the open-label ex-
tension trial of LCM or who did not complete the Titration 
or Maintenance Phases.
A Baseline seizure frequency of ≥4 partial-onset seizures 
per 28 days on average was deemed sufficiently high to 
detect both decreases and increases in seizure frequency. 
An 8-weeks Baseline Phase was considered necessary to 
adequately assess Baseline seizure frequency due to spon-
taneous fluctuations of seizure frequency in this subject 
population. Furthermore, the duration of the Maintenance 
Phase (12 weeks) was chosen due to regulatory guidance 
(European Medicines Agency [EMEA]) that suggests a 12-
week Maintenance Phase to have an adequate duration to 
evaluate efficacy.
Two primary variables were defined in each of these trials. 
For the US FDA, the primary variable was the change in par-
tial seizure frequency per 28 days from Baseline to the Main-
tenance Phase. For the EMEA, the primary variable was the 
proportion of responders, or patients experiencing a ≥50% 
reduction in partial seizure frequency from Baseline to the 
Maintenance Phase.[16,17,18,19] 
Analysis populations for post-hoc analyses
The safety set for the pooled data and the subset of patients 
taking at least one concomitant traditional sodium channel 
blocking AED included patients who took at least 1 dose of 
trial medication. 
The efficacy set for the pooled data and also the subset of 
patients taking at least one concomitant traditional sodium 
channel blocking AED included patients who took at least 1 
dose of trial medication and had at least 1 post-baseline ef-
ficacy assessment in the Maintenance Phase. Patients who 
dropped-out during titration are therefore not included as 
part of the efficacy assessment. By excluding dropouts dur-
ing Titration, Intention To Treat (ITT) Maintenance analysis 
better reflects dosing as intended by the protocol while 
still using an ITT approach for subjects assessed during the 
Maintenance Phase.
Results
Demographics: ITT population consisted of 1294 patients 
with a mean age of 38.6 years. Approximately half of the 
patients (51.1%) were females. Most of the patients (91.7%) 
were Caucasians and the mean BMI for the ITT population 
was 26.8 kg/m2. Average time since diagnosis was 23.7 years. 
Almost half of the patients (45.2%) tried 7 or more AEDs dur-
ing their lives, and distribution of 1, 2, and 3 concomitant 
AED usage was 15.5%, 62:4% and 22.0%, respectively.
The majority (82%) of the patients in the lacosamide clini-
cal trials were taking at least one traditional sodium channel 
blocking AED and demographics for this sub-group is simi-
lar to the overall pooled patient population. Most patients 
(78-79%) had received 4 or more lifetime AEDs, with 45-46% 
reporting at least 7 lifetime AEDs. Most patients were using 
at least 2 AEDs concomitantly, with 22%-25% using 3 AEDs 
+/- concomitant VNS. 
Efficacy (50% Responder Rates): In patients taking tradi-
tional sodium channel blocking AEDs, lacosamide 400 and 
600 mg (unapproved dose) showed a significantly greater 
proportion of 50% responders compared to placebo.
In both the pooled Phase II/III population and in those treat-
ed with traditional sodium channel blocking AEDs, 50% 
responder rates were significantly higher in the lacosamide 
400 and 600 mg/day dose groups compared to placebo.
While no specific comparisons were done, the 50% respond-
er rates appeared approximately similar in both groups at 
approved doses.
Safety: For the group of patients taking at least 1 traditional 
sodium channel blocking AED, the same treatment emer-
gent adverse events (TEAEs) as in the total Phase II/III popu-
lation occurred at an incidence of at least 5% and greater 
than placebo. There were no additional TEAEs for the so-
dium channel group that met this criterion. The overall pat-
tern and dose relationship of common AEs was similar in 
both groups.
The incidence of TEAEs leading to discontinuation in ≥1% 
of patients randomized to lacosamide in the pooled Phase 
II/III population and incidence of discontinuation due to 
those same TEAEs in patients treated with traditional so-
dium channel blocking AEDs were examined. One addi-
tional TEAE (tremor, 1.0%) led to discontinuation in ≥1% of 
patients treated with traditional sodium channel blocking 
AEDs that did not occur at a rate of ≥1% in the pooled Phase 
II/III population. Dizziness was the most common TEAE 
leading to discontinuation in both groups, and was the only 
TEAE leading to discontinuation in ≥5% of patients. The 
total percentage of subjects discontinuing for these TEAEs 
was similar in both groups.
Conclusion
LCM has a novel mode of action however the precise mech-
anism by which LCM exerts its anti-epileptic effects in hu-
mans remains to be fully elucidated. Adjunctive LCM thera-
py (400 mg and 600 mg) demonstrated significant efficacy 
in patients treated with traditional sodium channel block-
ing AEDs. Results are consistent with previous data analyses 
in which efficacy with LCM were demonstrated regardless 
of concomitant AED treatment regimen. The type and dose 
relationship of TEAEs appeared to be similar to the overall 
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patient pool and LCM is considered to be well tolerated at 
all dose levels. With its IV formulation LCM will expand the 
treatment options offered to physicians and patients, pro-
viding further convenience with the ability to switch be-
tween oral and IV formulations.
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